Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Therapeutic potential of interleukin-17 in inflammation and autoimmune diseases.

Yan JW, Wang YJ, Peng WJ, Tao JH, Wan YN, Li BZ, Mei B, Chen B, Yao H, Yang GJ, Li XP, Ye DQ, Wang J.

Expert Opin Ther Targets. 2014 Jan;18(1):29-41. doi: 10.1517/14728222.2013.843669. Epub 2013 Oct 23. Review.

PMID:
24147601
2.

Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.

Yao X, Huang J, Zhong H, Shen N, Faggioni R, Fung M, Yao Y.

Pharmacol Ther. 2014 Feb;141(2):125-39. doi: 10.1016/j.pharmthera.2013.09.004. Epub 2013 Sep 27. Review.

PMID:
24076269
3.

Update on the role of Interleukin 17 in rheumatologic autoimmune diseases.

Konya C, Paz Z, Apostolidis SA, Tsokos GC.

Cytokine. 2015 Oct;75(2):207-15. doi: 10.1016/j.cyto.2015.01.003. Epub 2015 May 28. Review.

PMID:
26028353
4.

Therapeutic potential of STAT4 in autoimmunity.

Liang Y, Pan HF, Ye DQ.

Expert Opin Ther Targets. 2014 Aug;18(8):945-60. doi: 10.1517/14728222.2014.920325. Epub 2014 May 20. Review.

PMID:
24844303
5.

Interleukin-23: as a drug target for autoimmune inflammatory diseases.

Tang C, Chen S, Qian H, Huang W.

Immunology. 2012 Feb;135(2):112-24. doi: 10.1111/j.1365-2567.2011.03522.x. Review.

6.

IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential.

Zhu S, Qian Y.

Clin Sci (Lond). 2012 Jun;122(11):487-511. doi: 10.1042/CS20110496. Review.

PMID:
22324470
7.

The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases.

Toussirot E.

Inflamm Allergy Drug Targets. 2012 Apr;11(2):159-68. Review.

PMID:
22280236
8.

IL-17 in Chronic Inflammation: From Discovery to Targeting.

Beringer A, Noack M, Miossec P.

Trends Mol Med. 2016 Mar;22(3):230-41. doi: 10.1016/j.molmed.2016.01.001. Epub 2016 Jan 31. Review.

PMID:
26837266
9.

The Th17 pathway as a therapeutic target in rheumatoid arthritis and other autoimmune and inflammatory disorders.

Roeleveld DM, van Nieuwenhuijze AE, van den Berg WB, Koenders MI.

BioDrugs. 2013 Oct;27(5):439-52. doi: 10.1007/s40259-013-0035-4. Review.

PMID:
23620106
10.

Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses.

Fujimoto M, Serada S, Mihara M, Uchiyama Y, Yoshida H, Koike N, Ohsugi Y, Nishikawa T, Ripley B, Kimura A, Kishimoto T, Naka T.

Arthritis Rheum. 2008 Dec;58(12):3710-9. doi: 10.1002/art.24126.

11.

Interleukin-17: a new paradigm in inflammation, autoimmunity, and therapy.

Kramer JM, Gaffen SL.

J Periodontol. 2007 Jun;78(6):1083-93. Review.

PMID:
17539723
12.

Effect of IL-17A blockade with secukinumab in autoimmune diseases.

Patel DD, Lee DM, Kolbinger F, Antoni C.

Ann Rheum Dis. 2013 Apr;72 Suppl 2:ii116-23. doi: 10.1136/annrheumdis-2012-202371. Epub 2012 Dec 19. Review.

PMID:
23253932
13.

Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases.

Antonelli A, Ferrari SM, Giuggioli D, Ferrannini E, Ferri C, Fallahi P.

Autoimmun Rev. 2014 Mar;13(3):272-80. doi: 10.1016/j.autrev.2013.10.010. Epub 2013 Nov 2. Review.

PMID:
24189283
14.

Th17 cells in inflammation and autoimmunity.

Singh RP, Hasan S, Sharma S, Nagra S, Yamaguchi DT, Wong DT, Hahn BH, Hossain A.

Autoimmun Rev. 2014 Dec;13(12):1174-81. doi: 10.1016/j.autrev.2014.08.019. Epub 2014 Aug 23. Review.

PMID:
25151974
15.

Autoimmune inflammation from the Th17 perspective.

Furuzawa-Carballeda J, Vargas-Rojas MI, Cabral AR.

Autoimmun Rev. 2007 Jan;6(3):169-75. Epub 2006 Nov 14.

PMID:
17289553
16.

Interleukin-17 and systemic lupus erythematosus: current concepts.

Nalbandian A, Crispín JC, Tsokos GC.

Clin Exp Immunol. 2009 Aug;157(2):209-15. doi: 10.1111/j.1365-2249.2009.03944.x. Review.

17.

[Immune regulation by IL-27 for therapeutic usage].

Yoshida H.

Nihon Rinsho Meneki Gakkai Kaishi. 2009 Aug;32(4):202-13. Review. Japanese.

18.

Therapeutic potential of IL-27 in systemic lupus erythematosus.

Pan HF, Tao JH, Ye DQ.

Expert Opin Ther Targets. 2010 May;14(5):479-84. doi: 10.1517/14728221003769911. Review.

PMID:
20350048
19.

The IL-17 pathway as a major therapeutic target in autoimmune diseases.

Hu Y, Shen F, Crellin NK, Ouyang W.

Ann N Y Acad Sci. 2011 Jan;1217:60-76. doi: 10.1111/j.1749-6632.2010.05825.x. Epub 2010 Dec 13. Review.

PMID:
21155836

Supplemental Content

Support Center